Research programme: motor neuron disease gene therapy - Oxford BioMedica
Alternative Names: Amyotrophic lateral sclerosis gene therapy - Oxford BioMedica; MoNuDin; OXB-103; SMN-1G; Spinal muscular atrophy gene therapy - Oxford BioMedicaLatest Information Update: 06 Oct 2021
At a glance
- Originator Oxford BioMedica; The Cleveland Clinic Foundation
- Developer Oxford BioMedica
- Class Gene therapies; Spinal muscular atrophy gene therapies
- Mechanism of Action Gene transference; Survival of motor neuron 1 protein expression stimulants; Vascular endothelial growth factor A expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Amyotrophic lateral sclerosis; Motor neuron disease
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Spinal muscular atrophy
Most Recent Events
- 22 Sep 2021 Discontinued - Preclinical for Amyotrophic lateral sclerosis in United Kingdom (IM)
- 24 Oct 2018 Preclinical development in Amyotrophic lateral sclerosis is ongoing in United Kingdom (Oxford BioMedica pipeline, October 2018)
- 24 Oct 2018 Discontinued - Preclinical for Spinal muscular atrophy in United Kingdom (IM)